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Abstract
Heart disease is a major cause of morbidity and premature mortality. Cardiomyopathy is
an anatomic and pathologic condition associated with muscle and electrical dysfunction
of the heart, often leading to heart failure–related disability. Dilated cardiomyopathy
caused by mutations in A-type lamin gene (i.e., LMNA cardiomyopathy) is characterized
by an increase in both myocardial mass and volume. The ventricular walls become thin
and stretched, compromising cardiac contractility and ultimately resulting in poor left
ventricular function. Despite current strategies to aggressively manage “LMNA cardio-
myopathy,” the disorder remains a common cause of heart failure with decreased ejection
fraction, and a prevalent diagnosis in individuals is referred for cardiac transplantation.
Despite progress in reducing “LMNA cardiomyopathy”–relatedmortality, hospitalizations
remain very frequent and rates of readmission continue to rise. It appears important and
necessary to further increase our knowledge on the pathophysiology of “LMNA cardio-
myopathy” to unveil novel molecular/cellular mechanisms to target future therapeutic
approaches.
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1. Introduction
Cardiomyopathy, a major cause of morbidity and premature mortality in developed countries,
is an anatomic and pathologic condition associated with muscle and electrical dysfunction of
the heart, often leading to heart failure-related disability, which is a staggering clinical and
public health problem. The mechanical component of the heart is liable for pumping blood
throughout the body. The electric component, as for it, produces a rhythm for the blood to be
pumped correctly. Hence, both components are tightly connected and regulated. Most com-
mon symptoms of dilated cardiomyopathy are shortness of breath, leg swelling, decreased
exercise tolerance, fatigue, dizziness, coughing or wheezing, weight gain, and palpitation.
Given the diversity in severity of symptoms in dilated cardiomyopathy, the disease is not
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always diagnosed. Cardiomyopathies are a clinically heterogeneous group of cardiac muscle
disorders [1]. Cardiomyopathies have historically been broken down into several major phe-
notypic categories. Dilated cardiomyopathy, the most common form, is a condition where the
heart muscle becomes enlarged and weakened, resulting in poor left ventricular function.
Despite current strategies to aggressively manage dilated cardiomyopathy, the disorder
remains a common cause of heart failure with a decrease below 45% of ejection fraction and a
referring for cardiac transplantation. Notwithstanding progress in reducing heart failure-
related mortality, hospitalizations for heart failure remain very frequent and rates of
readmissions continue to rise. It appears important and necessary to increase our knowledge
on the pathophysiology of cardiomyopathies to unveil novel molecular/cellular mechanisms
for future therapeutic approaches.
2. Inherited cardiomyopathies
While the most common cardiomyopathies are secondary to acquired conditions, many are
inherited. Genetic mutations have been identified in 25–35% of patients presenting dilated
cardiomyopathy. These mutations affect genes that encode components of a wide variety of
cellular compartments and pathways, including the nuclear envelope (e.g., LMNA, EMD), the
contractile apparatus (e.g.,MYH7, ACTC1, TPM1, TTN), the force transduction apparatus (e.g.,
MLP, DES, TNNT2), and calcium handling (e.g., SERCA). The cardiac cell is composed of a
complex network of proteins linking the sarcomere to the sarcolemma and the extracellular
matrix, providing structural support for subcellular structures and transmitting mechanical
signals within and between cells (Figure 1). Mutations in genes encoding proteins of the
sarcolemma are disrupting the anchoring and hence abrogate the transmission of the force
Figure 1. Cellular localizations of proteins involved in dilated cardiomyopathies.
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generated by muscle contraction. Muscle contraction is due to the interaction between an actin
filament and myosin heavy chain. Mutations in genes encoding contractile elements were
identified as the cause of dilated cardiomyopathy. Functional units of striated muscle are
called sarcomeres. Because the generated power of muscle contraction is transmitted to adja-
cent sarcomeres through the Z-disk, mutations in genes encoding proteins of the Z-disk causes
also dilated cardiomyopathy. Part of hereditary dilated cardiomyopathies is caused by muta-
tions in the genes encoding proteins of the nuclear envelope. Hence, disruption of the links
from the sarcolemma to the sarcomere and nucleus could have a “domino effect,” which leads
to the disruption of systolic function and to the development of dilated cardiomyopathy.
3. LMNA cardiomyopathy
Among the causing genes of dilated cardiomyopathy, it has been estimated that mutations in
LMNA, encoding nuclear lamin A/C [2], accounts for about 5–10% of familial dilated cardio-
myopathy, thus representing one of the major causative genes. Affected patients often exhibit
early conduction defects before left ventricle dysfunction and dilatation occur [3]. “LMNA
cardiomyopathy” usually presents in early to mid-adulthood with symptomatic conduction
system disease or arrhythmias or with symptomatic dilated cardiomyopathy (Figure 2A).
“LMNA cardiomyopathy” has an intrusive clinical progression with higher rates of aggressive
arrhythmias and faster course toward heart failure than most other cardiac diseases. Given the
increased awareness among physicians, cardiologists are now facing difficult queries regard-
ing patient management. These queries concern the use of defibrillators in order to avoid
sudden death from aggressive ventricular arrhythmias and pharmacological interventions to
improve heart failure symptoms. Once dilated cardiomyopathy is detected clinically, the
management for “LMNA cardiomyopathy” follows the standard of care for heart failure. It is
unclear whether early institution of these therapeutic agents prior to detectable cardiac dys-
function can modify the aggressive nature of “LMNA cardiomyopathy.” There is no definitive
treatment for the progressive cardiac dilatation and loss of contractility in “LMNA cardiomy-
opathy” short of heart transplantation [4].
4. A-type nuclear lamins
The LMNA gene, on chromosome 1q21.2-21.3, encodes nuclear A-type lamins. Lamin A and
lamin C, the major somatic A-type lamins, arise via alternative splicing of pre-mRNA [5]
(Figure 3A). Lamin A is primarily synthesized as a precursor, the prelamin A. Prelamin A has
a particular C-terminal amino acid tail, which undergoes several enzymatic reactions to pro-
duce mature lamin A. Two other genes, LMNB1 and LMNB2, encode lamins B1 and B2,
respectively. Lamins are class V intermediate filament proteins that polymerize to form the
nuclear lamina (Figure 3B), a fibrous network underlining the inner nuclear membrane of
most eukaryotic cells (Figure 3C) [6–8]. The nuclear lamina is bounded to the inner nuclear
membrane via interactions with integral proteins and to the chromatin. It has also been shown
that lamin A/C can also interact with the cytoskeleton, through the linker of nucleoskeleton
and cytoskeleton (“LINC”) complex [9]. One function of the lamina is to provide structural
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support to the nucleus. Nuclear lamins have also been implicated in processes such as chro-
matin organization, gene regulation, DNA replication, and RNA splicing [10]. However, the
specific mechanistic roles of lamins in these processes, particularly in a cell- or tissue-type–
specific context, remain obscure.
Figure 2. Cardiac symptoms of “LMNA cardiomyopathy (A) and pathological mechanisms (B).
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5. Pathogenesis
Identification of disease-causing mutations in the heart has contributed to the delineation of
“LMNA cardiomyopathy.” However, much work remains in elucidating the specific cellular
mechanisms of the disease. Several hypotheses have been proposed attempting to link the
Figure 3. Nuclear lamins: structure (A), organization (B), and cellular localization (C). Modified from [10].
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pathophysiology of “LMNA cardiomyopathy” to known or emerging functions of lamin A/C.
Among these functions include those based on that lamin A/C likely have in maintaining the
mechanical integrity of cells subject to external and internal cues and signal transduction (i.e.,
the mechanical stress hypothesis). The “mechanical stress hypothesis” is attractive when trying
to explain striated muscle diseases. It is based on the premise that the striated muscles are
constantly subjected to mechanical forces and that mutations in “nucleocytoskeletal” support
elements make them susceptible to damage from recurrent stress. Mouse models have been
extremely helpful in deciphering crucial mechanisms, which could partially explain the path-
ogenesis of the disease. The development of Lmna−/− mice by Sullivan and colleagues was the
first animal model of the disease [11]. Since, other models (knock-in and transgenic) have been
created to study the cardiac dysfunction caused by LMNA mutation [12–15]. We and others
reported an aberrant cardiac activation of signaling pathways in “LMNA cardiomyopathy”
[16, 17] in mice and human, which participate to the development of contractile dysfunction
(mitogen-activated protein kinase (MAPK) signaling, AKT/mTOR signaling, TGF-β signaling,
etc.) [16, 18, 19] and electrical disturbances (connexin 43 remodeling, apoptosis, Hf1b expres-
sion) (Figure 2B).
MAPK signaling—One of the most prevalent and best-characterized responses to mechanical
stress is the phosphorylation of proteins, which could be mediated by mitogen-activated
protein kinase (MAPK) signaling pathway. Genes encoding proteins in MAPK signaling path-
way demonstrated significantly altered expression in hearts of Lmna H222P mice by
transcriptomic analysis [16]. We demonstrated an aberrant activation of ERK1/2, JNK, and
p38α signaling, three main branches of MAPK signaling pathway involved in cellular
mechanotransduction, in hearts from Lmna H222P mice, as early as 4 weeks of age [16, 17].
Our work proved that the activation of MAPK signaling pathway preceded the cardiac dys-
function of Lmna H222P mice and that it is a consequence of alterations in lamin A/C and not
secondary to nonspecific effects. Accordingly, lamin A/C-deficient fibroblasts subjected to
cyclic strain respond with decreased expression of the mechanosensitive genes, which are
downstream targets of the MAPK pathway [20].
AKT/mTOR signaling—We showed that the Lmna pH222P mutation results in aberrant acti-
vation of the AKT/mTOR signaling cascade, downstream of the MAPK pathway [18]. Given
that activated mTOR inhibits autophagic responses and reduces tolerance to energy deficits,
the heart is therefore unable to compensate for increased energy demand and, over time,
develops muscle damage and dilated cardiomyopathy.
TGF-β signaling—Cardiac fibrosis exacerbates the clinical progression of heart failure. We
showed that Lmna H222P mice had elevated expression of TGF-β signaling as early as 12
weeks of age, which is a time that preceded development of both cardiac fibrosis and the onset
of overt cardiac dysfunction [13, 19]. Our observations indicate that TGF-β is a mediator of the
cardiomyopathy that develops as a result of LMNAmutations.
Connexin 43 remodeling—Gap junction communications describe the electrical coupling of cells
through specialized cell contacts called gap junctions. In adult heart, connexin 43 is expressed
in the atrial and ventricular working (contractile) myocardium. The working cardiomyocytes
of the ventricle are extensively interconnected by clusters of connexin 43 located at the
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intercalated disks. The intercalated disks of working ventricular myocardium have a step-like
configuration, with the gap junctions situated predominantly in the “horizontal” facing seg-
ments of these steps rather than the vertical segments [21, 22]. Features of gap junction
organization encourage preferential propagation of the impulse in the longitudinal axis, thus
contributing to the normal pattern of anisotropic spread of the impulse of healthy ventricular
myocardium. The most striking form of structural remodeling connexin 43 is typically
scattered in disordered fashion over the lateral surfaces in the heart from Lmna N195K mice
(i.e., lateralization) [12].
Apoptosis—Apoptosis in all metazoan cells is mediated by caspases, a multigene family of
cysteine proteases that hydrolyzes peptide bonds carboxyl to aspartic acid residues. Once
activated, caspases cut cellular proteins, leading to the apoptotic demise of the cell. During
the past few years, there has been accumulating evidence in both human and animal models
suggesting that apoptosis may be an important mode of cell death during heart failure [23].
Myocyte apoptosis has been reported in the atrioventricular tissue from Lmna+/− mice [24],
which could account for the evolution of electrophysiologic dysfunction.
Hf1b/Sp4—This transcription factor has been described as important for the development of
the cardiac conduction system [25]. Mounkes and colleagues found that expression and local-
ization of Hf1b/Sp4 were altered in the heart from LmnaN195K mice [12]. Strikingly, this study
reported that Hf1b/Sp4 was not found in the ventricles and was strongly expressed in the atria
in the heart from Lmna N195K mice, which mirror the localization in control animals. This
finding needs further analysis.
The exact mechanisms by which defects in nuclear lamins cause dysregulated signaling remain
to be elucidated.
6. Treatments
Advances in molecular techniques have improved the understanding of mechanisms respon-
sible for cardiac dysfunction in “LMNA cardiomyopathy.” It is clear that mutations in nuclear
lamin A/C in cardiomyocytes can perturb cardiac function. Alterations in cardiomyocyte
function initiate cascades of cellular responses that attempt to compensate for these insults.
However, persistent responses at the cellular level lead to organ-wide alterations, which
correlated with sudden cardiac death and heart failure. Although there exists no treatment to
directly address the causes of “LMNA cardiomyopathy,” basic studies of the processes that
mediate cellular responses to cardiac stress have allowed the development of innovative
treatments that address the reduction of symptoms that include drugs that decrease blood
pressure (ACE inhibitors, angiotensin II receptor blockers, beta-blockers) and heart rate (beta-
blockers, calcium channel blockers, digoxin) to reduce the strain on the ventricular walls.
Utilization of animal and cellular models to further dissect the mechanisms of “LMNA cardio-
myopathy” and demonstrate efficacy of drugs that specifically target disease-causing path-
ways holds promise that further reduction in the mortality associated with “LMNA
cardiomyopathy” can be achieved [17–19, 26, 27].




In the past decade, there has been an extraordinary burst of researches on lamin A/C and the
nuclear lamina, which has been accelerated by attempts to explain the pathogenesis of
“LMNA cardiomyopathy.” One important unanswered question is how mutations in genes
expressed in most differentiated somatic cells lead to human disease affecting the cardiac
tissue. Within the next several years, we will likely have more clues to answer this question,
and these answers will hopefully lead to new ways to treat or prevent “LMNA cardiomyop-
athy.”
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